Evidence map›Paper›PMID 38425667›Full record

ArticleFrontiers in pediatrics2024

Norovirus in children under 2 years of age: an epidemiological study in Panama during the COVID-19 pandemic.

Rodrigo DeAntonio, Morgan Hess-Holtz, Leyda Abrego, Zeuz Capitan-Barrios, Leyla Hernandez Donoso, Tirza De León, Xavier Sáez Llorens, Brechla Moreno, John Gerard Weil

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Rodrigo DeAntonioCentro de Vacunación e Investigación CEVAXIN, The Panama Clinic, Panama City, Panama.
Morgan Hess-HoltzCentro de Vacunación e Investigación CEVAXIN, The Panama Clinic, Panama City, Panama.
Leyda AbregoInstituto Conmemorativo Gorgas de Estudios de la Salud, Departamento de Investigacion en Virologia y Biotecnologia, Panama City, Panama.
Zeuz Capitan-BarriosDepartamento de Microbiología y Parasitología, Facultad de Ciencias Naturales, Exactas y Tecnología, Universidad de Panama, Panama City, Panama.
Leyla Hernandez DonosoTakeda Pharmaceuticals International AG., Zurich, Switzerland.
Tirza De LeónCentro de Vacunación e Investigación CEVAXIN, The Panama Clinic, Panama City, Panama.
Xavier Sáez LlorensCentro de Vacunación e Investigación CEVAXIN, The Panama Clinic, Panama City, Panama.
Brechla MorenoInstituto Conmemorativo Gorgas de Estudios de la Salud, Departamento de Investigacion en Virologia y Biotecnologia, Panama City, Panama.
John Gerard WeilTakeda Pharmaceuticals International AG., Zurich, Switzerland.
Universidad de Panamá · PATakeda (Switzerland) · CHInstituto Conmemorativo Gorgas de Estudios de la Salud · PA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Norovirus infection is a common cause of acute gastroenteritis (AGE). Surveillance activities are important to aid investigation into effective norovirus control strategies, including vaccination. Here, we report ancillary findings related to the incidence, prevalence, and etiology of AGE caused by norovirus in Panama after adjustment of study methodology to comply with national coronavirus disease 2019 (COVID-19) mandates. Methods: In January 2020, children aged <2 years began enrolling into an epidemiological study in Panama to estimate the burden of norovirus in preparation for evaluating upcoming prevention strategies. This included an observational, longitudinal, community-based AGE surveillance study and a hospital-based AGE surveillance study. For the longitudinal study, healthy children aged 5-18 months were enrolled from January 6 through March 23, 2020, with a follow-up of approximately 6 months. The last participant was contacted on September 23, 2020. For the hospital-based study, starting on January 21, 2020, children aged <2 years who were admitted to the Hospital del Niño Dr. José Renán Esquivel in Panama City due to AGE were evaluated. The last sample was collected on September 29, 2020. Collected stool samples were tested for norovirus as well as astrovirus, sapovirus, and various enteropathogens. Unfortunately, this study was disrupted by the subsequent implementation of disease transmission control procedures for the COVID-19 pandemic, and the study methodology was revised to comply with COVID-19 mandates. Results: In the longitudinal surveillance cohort [ Discussion: This report demonstrates how the occurrence of the COVID-19 pandemic hindered the conduct of clinical trials. However, this also created unique research opportunities to investigate the potential impact of pandemic control measures on the etiology of infectious diarrheal disease.

Indexed as

COVID-19epidemiologygastroenteritisinfectious diarrheal diseasenorovirus

Identifiers

PMID38425667
PMCPMC10902054
OpenAlexW4391841728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.